title: Cutaneous lymphoproliferative disorders in organ transplant recipients: update 2014.
abstract: Post-transplant lymphoproliferative disorders (PTLD) are lymphoid or plasmacytic proliferations that develop after solid organ, bone marrow or stem cell transplantation. PTLD are the leading cause of cancer-related mortality and graft loss in both pediatric and adult solid organ transplant recipients (ORT). These disorders comprise a spectrum ranging from usually EBV-driven, mostly B-cell polyclonal proliferations to B- and T-cell lymphomas indistinguishable from their counterparts occurring in immunocompetent individuals. PTLD usually present in extranodal sites; isolated skin involvement of PTLD is rare. A recent multicenter European case series showed that primary cutaneous T-cell PTLD are more common than primary cutaneous B-cell PTLD, and along with its folliculotropic variant, mycosis fungoides (MF) is the most frequent form of posttransplant primary cutaneous T-cell lymphoma (CTCL). This case series also disclosed that primary cutaneous CD30+ lymphoproliferative disorders is the second most common posttransplant CTCL subtype, indicating that the spectrum of primary CTCL in OTR is similar to that in the general population. However, in contrast with the immunocompetent individuals, the prognosis of primary cutaneous CD30+ anaplastic large T-cell lymphoma is worse than posttransplant MF and than its counterpart in the general population which has an excellent prognosis. The recent case series indicated that the spectrum of primary cutaneous B-cell PTLD differs significantly from cutaneous B-cell lymphoma in the general population, with a predominance of EBV-associated forms. Currently, the best therapeutic intervention(s) for primary cutaneous PTLD remains unknown.
authors: Department of Dermatology Başkent University Faculty of MedicineAnkara, Turkey - denizs@baskent-ank.edu.tr.
authors: D
authors: D
authors: Seçkin
mesh_terms: D019317:Evidence-Based Medicine; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008221:Lymphoid Tissue / Q000187:drug effects*; D016393:Lymphoma, B-Cell / Q000139:chemically induced; D016410:Lymphoma, T-Cell, Cutaneous / Q000139:chemically induced; D008232:Lymphoproliferative Disorders / Q000139:chemically induced* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009182:Mycosis Fungoides / Q000139:chemically induced; D016377:Organ Transplantation / Q000009:adverse effects; D010950:Plasma Cells / Q000187:drug effects*; D012878:Skin Neoplasms / Q000139:chemically induced; D066027:Transplant Recipients
chemical_list: D007166:Immunosuppressive Agents